Susanna Naggie MD MHS
Associate Professor, Medicine, Duke University School of Medicine; Director, Infectious Disease Research, Duke Clinical Research Institute; Staff Physician, Durham VA Medical Center
Join to View Full Profile
2100 Erwin RdDurham, NC 27705
Phone+1 919-684-8111
Dr. Naggie is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Duke University HospitalFellowship, Infectious Disease, 2007 - 2009- Duke University HospitalResidency, Internal Medicine, 2002 - 2005
Johns Hopkins University School of MedicineClass of 2002
Certifications & Licensure
NC State Medical License 2002 - 2025
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Infectious Disease
Clinical Trials
- Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute Hepatitis C Virus (HCV) Infection Start of enrollment: 2014 May 30
- Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection Start of enrollment: 2019 Nov 20
Publications & Presentations
PubMed
- Electronic Clinical Decision Support Tools to Manage Patients with Lower Respiratory Tract Infection: Clinicians' Perspectives in Sri Lanka.Warsha De Zoysa, Dhammika Palangasinghe, Champica Bodinayake, Ajith Nagahawatte, Jayani Gamage
The American Journal of Tropical Medicine and Hygiene. 2025-03-11 - Impact of a minimal monitoring HCV treatment approach on Health-Related Quality of Life.Thiago S Torres, Pooja T Saha, Laura Smeaton, Chanelle Wimbish, Dimas Alexandre Kliemann
Quality of Life Research. 2025-02-28 - Duke Research at Pickett: The evolution of a free-standing research site partnering with communities toward health equity advancement.Laura Van Althuis, Sally Taylor, Debra Freeman, Stephanie Freel, Lynn Sutton
Journal of Clinical and Translational Science. 2025-01-01
Press Mentions
What Ivermectin Can (And Can’t) DoMarch 31st, 2025- Asthma Drug Did Not Reduce Symptom Duration in Mild to Moderate COVIDOctober 22nd, 2024
- Time to Sustained Recovery Among Outpatients with COVID-19 Receiving Montelukast vs PlaceboOctober 18th, 2024
- Join now to see all
Grant Support
- Task A: Early Phase Clinical Trial Units (EPCTU)DUKE UNIVERSITY2022–2025
- Task A: Early Phase Clinical Trial Units (EPCTU)DUKE UNIVERSITY2022–2025
- Task A: Early Phase Clinical Trial Units (EPCTU)DUKE UNIVERSITY2022–2025
- ACTIV-6DUKE UNIVERSITY2022–2025
- Task A: Early Phase Clinical Trial Units (EPCTU)DUKE UNIVERSITY2022–2025
- Applying an 'omics' approach to predict hepatic decompensation events and hepatocellular carcinoma in veterans after HCV cure with direct acting antiviral therapyDURHAM VA MEDICAL CENTER2021–2025
- Applying an 'omics' approach to predict hepatic decompensation events and hepatocellular carcinoma in veterans after HCV cure with direct acting antiviral therapyDURHAM VA MEDICAL CENTER2021–2025
- Applying an 'omics' approach to predict hepatic decompensation events and hepatocellular carcinoma in veterans after HCV cure with direct acting antiviral therapyDURHAM VA MEDICAL CENTER2021–2025
- Applying an 'omics' approach to predict hepatic decompensation events and hepatocellular carcinoma in veterans after HCV cure with direct acting antiviral therapyDURHAM VA MEDICAL CENTER2021–2025
- Applying an 'omics' approach to predict hepatic decompensation events and hepatocellular carcinoma in veterans after HCV cure with direct acting antiviral therapyDURHAM VA MEDICAL CENTER2021–2025
- ACTIV-6DUKE UNIVERSITY2021–2025
- Applying an 'omics' approach to predict hepatic decompensation events and hepatocellular carcinoma in veterans after HCV cure with direct acting antiviral therapyDURHAM VA MEDICAL CENTER2021–2025
- ACTIV-6DUKE UNIVERSITY2021–2025
- Applying an 'omics' approach to predict hepatic decompensation events and hepatocellular carcinoma in veterans after HCV cure with direct acting antiviral therapyDURHAM VA MEDICAL CENTER2021–2025
- ACTIV-6DUKE UNIVERSITY2021–2025
- ACTIV-6DUKE UNIVERSITY2021–2025
- Centers for AIDS Research (CFAR)DUKE UNIVERSITY2005–2025
- Centers for AIDS Research (CFAR)DUKE UNIVERSITY2005–2025
- Centers for AIDS Research (CFAR)DUKE UNIVERSITY2005–2025
- Vaccine and Treatment Evaluation Units: Phase IV Clinical Trial in Adults with Community Acquired Pneumonia to Assess the Effect of Early Empiric Antifungal Treatment of Coccidioidomycosis PneumoniaDUKE UNIVERSITY2015–2024
- Vaccine and Treatment Evaluation Units: Phase IV Clinical Trial in Adults with Community Acquired Pneumonia to Assess the Effect of Early Empiric Antifungal Treatment of Coccidioidomycosis PneumoniaDUKE UNIVERSITY2015–2024
- Vaccine and Treatment Evaluation Units: Phase IV Clinical Trial in Adults with Community Acquired Pneumonia to Assess the Effect of Early Empiric Antifungal Treatment of Coccidioidomycosis PneumoniaDUKE UNIVERSITY2015–2024
- Vaccine and Treatment Evaluation Units: Phase IV Clinical Trial in Adults with Community Acquired Pneumonia to Assess the Effect of Early Empiric Antifungal Treatment of Coccidioidomycosis PneumoniaDUKE UNIVERSITY2015–2024
- Vaccine and Treatment Evaluation Units: Phase IV Clinical Trial in Adults with Community Acquired Pneumonia to Assess the Effect of Early Empiric Antifungal Treatment of Coccidioidomycosis PneumoniaDUKE UNIVERSITY2015–2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
